SALARAS

Salaras is a clinical-stage biotechnology company focused on the development of novel small molecule inhibitors for the treatment of cancer. The company's lead program, SAL-003, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor currently being evaluated in Phase 1 clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML) and other hematologic malignancies. Salaras aims to address significant unmet medical needs in oncology by targeting key regulatory pathways involved in tumor cell survival and proliferation. The company is also exploring the potential of its CDK9 inhibitor in various solid tumor indications, leveraging its precision medicine approach to improve patient outcomes.